

1 **Clinical Characteristics Hospitalized Patients with SARS-Cov-2 and HBV Co-**  
2 **infection**

3 Xiaoping Chen<sup>1\*#</sup>, Qunqun Jiang<sup>1\*</sup>, Zhiyong Ma<sup>1\*</sup>, Jiaxin Ling<sup>2</sup>, Wenjia Hu<sup>1</sup>, Qian  
4 Cao<sup>1</sup>, Pingzheng Mo<sup>1</sup>, Rongrong Yang<sup>1</sup>, Shicheng Gao<sup>1</sup>, Xien Gui<sup>1</sup>, Yong Xiong<sup>1</sup>,  
5 Jinlin Li<sup>3#</sup>, Yongxi Zhang<sup>1#</sup>

6  
7 <sup>1</sup> Department of Infectious Diseases, Zhongnan Hospital of Wuhan University,  
8 No.169, Donghu Road, Wuchang District, 430071 Wuhan, Hubei Province, China

9 <sup>2</sup> Department of Medical Biochemistry and Microbiology, Zoonosis Science Center,  
10 University of Uppsala, Uppsala, Sweden

11 <sup>3</sup> Department of Cell and Molecular Biology, Karolinska Institutet, 171 65, Stockholm,  
12 Sweden.

13

14

15

16 \* Xiaoping Chen, Qunqun Jiang, and Zhiyong Ma contributed equally to this work

17

18 <sup>#</sup>Corresponding Author: Xiaoping Chen, MD & PhD, Department of infectious  
19 diseases, Zhongnan Hospital of Wuhan University, No.169, Donghu Road, Wuchang  
20 District, Wuhan City, Hubei Province, P.R. China; E-mail: [alackcn@126.com](mailto:alackcn@126.com); Tel:  
21 86-27-67812880. or Jinlin Li, PhD, Department of Cell and Molecular Biology,  
22 Karolinska Institutet, 171 65, Stockholm, Sweden; E-mail : [jinlin.li@ki.se](mailto:jinlin.li@ki.se). or Yongxi  
23 Zhang, MD & PhD, Department of infectious diseases, Zhongnan Hospital of Wuhan  
24 University, No.169, Donghu Road, Wuchang District, Wuhan City, Hubei Province,  
25 P.R. China; E-mail: [znact1936@126.com](mailto:znact1936@126.com), Tel: 86-27-67812880.

26

27

## 28 **Summary**

### 29 *Background*

30 The novel coronavirus infected disease (COVID-19) caused by SARS-CoV-2 has  
31 been characterized as a pandemic, which causes a serious public health challenge in  
32 the world. A very large group of patients infected by HBV has been reported  
33 worldwide, especially in China. In order to answer whether specific treatment strategy  
34 on the patients coinfecting with HBV and SARS-Cov-2, it requires profound  
35 understanding of the clinical characteristics on those patients. However, the impacts  
36 of SARS-CoV-2 infection on HBV patients remain largely unknown.

### 37 *Methods*

38 In this retrospective investigation, we included 123 COVID-19 patients admitted to  
39 Zhongnan Hospital of Wuhan University, Wuhan, China, from January 5 to March 7,  
40 2020. All enrolled patients are the laboratory confirmed COVID-19 pneumonia cases  
41 according to the criteria reported previously. A total of 123 patients were analyzed for  
42 their Clinical records, laboratory results including the diagnosis of HBV infection  
43 and liver function.

### 44 *Findings*

45 Among 123 confirmed COVID-19 patients, the mean age was 51 years old and 59.3%  
46 were females. Fifteen were previously HBV infected patients, 66.7% of them were  
47 males (10/15), patients with HBV infection appeared to have a higher incidence of  
48 liver cirrhosis and an increased level of total bilirubin. Seven (46.7%) patients with  
49 HBV infection were defined as severe cases, while the severity rate was 24.1% for the  
50 patients without HBV infection. The mortality of patients with HBV infection was  
51 13.3% (2/15) compared to 2.8% (2/108) for the patients without HBV infection.

### 52 *Conclusions*

53 SARS-Cov-2 infection may cause Live function damage in COVID-19 cases and the  
54 patients with HBV infection are likely to have more severe outcome.

55 **Keywords.** COVID-19; Hepatitis B virus, liver function, outcome

56

57 **Funding**

58 This study was funded by the Zhongnan Hospital of Wuhan University Science,  
59 Technology and Innovation Seed Fund, grant number znp2018007. The funders had  
60 no role in study design, data collection or analysis, decision to publish or preparation  
61 of the manuscript. The authors declared no competing interests.

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

## 81 Introduction

82

83 In early December 2019, there was an outbreak of novel coronavirus-associated  
84 pneumonia in Wuhan, China. The virus was spreading rapidly to other cities of China  
85 and accumulating cases had been reported in coming days.(1). According to the  
86 announcement of the World Health Organization (WHO), the disease has been  
87 officially named as Coronavirus Disease-2019 (COVID-19) (2). The etiology of the  
88 disease was identified to be a novel  $\beta$ -coronavirus, named as severe acute respiratory  
89 syndrome coronavirus 2 (SARS-CoV-2) based on the phylogenetic relationship with  
90 SARS-CoV. On March 11, 2020, WHO declared the outbreak of SARS-CoV-2 as a  
91 pandemic. So far, more than 290,000 people in over 180 countries or territories have  
92 reported COVID-19 cases, and more than 12,000 people have died according to data  
93 from WHO (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>).  
94 Around 25% COVID-19 cases were reported in Wuhan, China.

95 In addition to the recent emerged SARS-CoV-2, Hepatitis B virus (HBV) is one of the  
96 viruses which causes a global infection and threat public health. In worldwide, the  
97 prevalence of HBsAg is about 3.9%. As high as 290 million patients are suffering  
98 from chronic HBV infection and about 650,000 patients die from HBV infection due  
99 to liver failure, liver cirrhosis and hepatocellular carcinoma (HCC) each year(3, 4).  
100 According to a nationwide epidemiological survey of population whose ages range  
101 from 1 to 59y in China, 2016, the prevalence of HBsAg was 7.2%. Around 93 million  
102 patients were positive for HBV infection and 20 million patients were diagnosed as  
103 chronic hepatitis B infection(5, 6).

104 Previous studies have shown that SARS-CoV-2 has a capacity to infect multiply  
105 organs including upper respiratory tract, lung, kidney probably due to the expression  
106 of SRAS-CoV-2 receptor, ACE2, on these tissues(7). A recent research has  
107 demonstrated that SARS-CoV-2 infection was associated with live function damage  
108 in COVID-19 patients(8). Taking consideration of large group of people with HBV  
109 infection, the risk of SARS-CoV-2 infection on patients with HBV infection requires  
110 a further assessment in order to design the specific treatment strategy. However, the  
111 impacts of SARS-CoV-2 infection on HBV patients are still not clear. For example,  
112 we do not yet know whether the SARS-CoV-2 infection is more severe in HBV

113 patients and we also do not have much knowledge about the impact of SARS-Cov-2  
114 on the course of HBV infection. In this retrospective study, we discovered that the  
115 liver impairment is a common feature in COVID-19 patients and as high as 46.7%  
116 patients with HBV infection develop to severe situation during the course of SARS-  
117 CoV-2 infection. This suggests that patients with HBV infection might be vulnerable  
118 group to SARS-CoV-2 infection.

119

## 120 **Methods**

121

### 122 Study design

123 From January 5 to February 7, 2020, 123 COVID-19 patients were enrolled in the  
124 study. Informed consents were obtained from all patients upon admission to the  
125 Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan,  
126 China. The clinical outcomes (ie, discharges, mortality, Hospital stays) were  
127 monitored up to March 7, 2020, the final date of follow-up.

128

### 129 Data collection

130 The information of enrolled patients including the demographic information, clinical  
131 manifestations, laboratory data including blood routine examination, liver function,  
132 Hepatitis B virus serological markers (HBsAg, anti-HBsAg, HBeAg, anti-HBeAg,  
133 anti-HBcAg, HBV-DNA), and outcome of disease, were collected and reviewed by  
134 two researchers to avoid subjective biases.

135 The diagnosis of COVID-19 was based on real-time RT-PCR. Throat swab samples  
136 were collected for extracting SARS-CoV-2 RNA from patients suspected of having  
137 SARS-CoV 2 infection as described anywhere(9). The diagnostic criteria of SARS-  
138 CoV-2 real-time RT-PCR were based on the recommendation by the National  
139 Institute for Viral Disease Control and Prevention, China  
140 (<http://ivdc.chinacdc.cn/gjhz/jldt/202002/P020200209712430623296.pdf>).

141 Severe patients were defined according to the Guideline of the treatment of COVID-  
142 19 (Version 6, 2020 Feb 18,  
143 [http://www.nhc.gov.cn/yzygj/s7653p/2020028334a8326dd94d329df351d7da8aefc2.s](http://www.nhc.gov.cn/yzygj/s7653p/2020028334a8326dd94d329df351d7da8aefc2.shtml)  
144 [html](http://www.nhc.gov.cn/yzygj/s7653p/2020028334a8326dd94d329df351d7da8aefc2.shtml)). Briefly, we categorize the patient as severe case if the symptoms of dyspnea  
145 show. The signs of dyspnea include any of the following features: shortness of  
146 breath, respiration rate  $\geq 30$ bpm, blood oxygen saturation  $\leq 93\%$  (at rest), PaO<sub>2</sub> /  
147 FiO<sub>2</sub>  $\leq 300$  mmHg, or pulmonary inflammation that progresses dramatically within  
148 24 to 48 hours > 50%.

149

150 Statistical analysis

151 The statistical analyses in this study was performed by the SPSS 17.0 software  
152 package. We utilized  $\chi^2$  tests or Fisher's exact tests for categorical variables. For  
153 normal distribution, *t-test* was applied to analyze the data, expressed as mean  $\pm$   
154 standard deviations. Regarding the non-normal distribution data, we used the Mann-  
155 Whitney U to do the test and the results were shown as of median (25%–75%  
156 interquartile range, IQR) A *p* value of < 0.05 was considered statistically significant.

157

158 The principle of medical ethics

159 This study was approved by the ethics board in Zhongnan Hospital of Wuhan  
160 University, Wuhan, China (No.2020011).

161

## 162 **Results**

163

### 164 **Baseline characteristics of COVID-19 patients with or without HBV infection**

165 A total of 123 patients with COVID-19 were enrolled in this study, including 50  
166 males and 73 females. Around 12.2% (15/123) of patients are also suffering from  
167 HBV infection. Males take up 66.7% (10/15) of patients coinfecting by HBV and

168 SARS-CoV-2 and seems to have a higher coinfection rate compared to females  
169 (p=0.0469, Table 1). The median age of total enrolled patients was 51.0 years (IQR,  
170 35.0-66.0; range, 20-96 years). The most common symptoms at the onset of illness  
171 were: fever (37.4–39.1°C, 69.1%), fatigue (54.5%), cough (50.4%), myalgia (32.5%),  
172 and less common: dyspnea (21.1%), Headache (16.3%) and diarrhea (17.1%). Among  
173 the 123 patients, thirty-five (28.5%) cases had underlying at least one comorbidity  
174 such as hypertension, cardiovascular disease, diabetes, malignancy, COPD and liver  
175 cirrhosis. Patients with HBV infection had a higher rate of liver cirrhosis (p=0.0390,  
176 Table 1). Seven of 15 patients (46.7%) with HBV infection develop to the severe  
177 situation, while the percentage of severe cases is much less (24.1%) in the COVID-19  
178 patients without HBV infection.

179 The treatment was mainly the supportive care (Table 1). Seventy-four patients were  
180 given antiviral (arbidol, orally, 200 mg, three times per day), and 74 with oxygen  
181 support. Antibiotic therapy, both orally and intravenous, were given as described in  
182 Table 1. Sixty-one patients received corticosteroids to suppress an excessive  
183 inflammatory activation. There is no significant difference of treatment between  
184 patients with or without HBV infection.

185

#### 186 **laboratory Findings of COVID-19 patients with or without HBV infection at** 187 **baseline**

188 The biochemical tests included measuring the level of alanine aminotransferase,  
189 aspartate aminotransferase, total bilirubin, albumin as well as recording prothrombin  
190 time, activated partial thromboplastin time, international normalized ratio, d-dimer  
191 and creatinine. All of these biochemical features were found normal; however, the  
192 level of total bilirubin was higher in patients with HBV infection (p=0.0178, Table 2).  
193 The blood counts of the patients with or without HBV infection showed lymphopenia  
194 ( $< 1.3 \times 10^9/L$ ).

195

#### 196 **Hepatitis B serological markers of COVID-19 patients with HBV infection**

197 Fifteen COVID-19 patients were examined to be HBsAg positive (5 females and 10  
198 males). The data of anti-HBsAg, HBeAg, anti-HBeAg and anti-HBcAg were  
199 available for 11 patients with ten patients HBeAg negative and one positive. The value  
200 of HBV-DNA was collected from 13 patients. The HBV-DNA level of 10 patients are  
201 more than 20 IU/ml (Table S1).

202

### 203 **Clinical outcome**

204 We observed the clinical outcome of 123 COVID-19 patients within 31 days of  
205 treatment. Eleven patients (73.4%) with HBV infection and 99 patients (91.6%)  
206 without HBV infection were discharged from the hospital according to the guideline.  
207 Two patients (13.3%) with HBV infection and 6 patients (5.6%) without HBV  
208 infection were still hospitalized. Two patients (13.3%) with HBV infection and 3  
209 patients (2.8%) without HBV infection were dead. Patients with HBV infection  
210 showed higher mortality rate compared to those COVID-19 patients without HBV  
211 infection (13.3% vs 2.8%, Table 2).

212

### 213 **Discussion**

214 Resemble to the other two coronaviruses, SARS-CoV and MERS, SARS-CoV-2 can  
215 cause patients severe respiratory symptoms and even leads to death with average  
216 mortality rate of 3.4% (according to the data reported from WHO) though most cases  
217 of COVID-19 are acute and resolve fast. Liver damage has been identified in around  
218 60% of patients suffering from SARS and viral RNA was detected by RT-PCR in  
219 liver tissue(10), which providing the evidence that SARS-CoV involved in liver injury.  
220 Liver impairment has been also reported in MERS patients(11). According to the  
221 clinical reports from different centers with large scale of COVID-19 cases, SARS-  
222 CoV-2 has been found to be associated with damage or dysfunction of liver tissue(9,  
223 12-18) and about 14% - 53% COVID-19 cases showed liver function damage with  
224 abnormal level of alanine aminotransferase (ALT) and aspartate aminotransferase  
225 (AST). Our study is in line with previous observations. We found in COVID-19 cases  
226 without HBV infection that about 50.9% (55/108) patients have the dysfunction of  
227 liver symptoms by measuring the level of ALT, AST, total bilirubin (TBIL), gamma-

228 glutamyltransferase (GGT), and alkaline phosphatase (ALP) during the disease  
229 progress. In our enrolled cases, we also discovered that there is higher incidence of  
230 abnormal liver function (81.8%, 27/33) in severe COVID-19 patients than did in mild  
231 cases(43.3%, 39/90, data not shown), which agrees with the study that lower  
232 incidence of AST abnormality was found in the cases diagnosed by CT scan on the  
233 subclinical stage than in the COVID-19 patients who were confirmed after onset of  
234 symptom(15). Therefore, liver function could be considered as one factor to indicate  
235 the progress of COVID-19.

236 According to other study from 1099 cases, around 23.7% of confirmed COVID-19  
237 patients have at least one comorbidity(13). Among these pre-existing chronic diseases,  
238 abnormal liver function is one of most common features in COVID-19 patients and  
239 severe patients are more likely to have HBV infection. In our research, about one out  
240 of five (21.8%) COVID-19 severe patients were found to coinfect with HBV infection.  
241 It has been suggested that liver impairment in COVID-19 patients could be due to the  
242 virus direct attack or resulted by other causes such as drug toxicity and systemic  
243 inflammation(18). To detect the viral RNA and viral particles from liver biopsies of  
244 COVID-19 patients will be helpful to elucidate if virus infect liver tissue. Our results  
245 pointed out that as high as around 50% of HBV patients were identified as severe  
246 COVID-19 cases. It is more likely that HBV patients will suffer from more severe  
247 situation during the disease progress when were encountered with SARS-CoV-2  
248 infection. In our enrolled cases, two patients with SARS-CoV and HBV coinfection  
249 died on admission. One patient died from severe liver disease, haptic sclerosis. And  
250 the other died from intestinal hemorrhage, which seems to be associated the  
251 impairment of gastrointestinal tract. More coinfection cases analyses are required to  
252 further understand whether SARS-CoV-2 infection aggerates the progress of pre-  
253 existing disease and thereby cause death. There are different phases for HBV chronic  
254 infection including immunotolerant, viral suppression under long-term treatment with  
255 nucleotide analogues. In our current study, we collected the data of HBV on 15  
256 coinfection patients at one time point, which were mainly used to identify HBV  
257 infection. More coinfection cases analysis is required to provide further evidences for  
258 evaluating the effects of SARS-CoV-2 infection on active HBV replication and live  
259 impairment at different time points for the HBV patients in different phases.

260 In conclusion, by respectively analyzing the patients with coinfection of SARS-CoV-  
261 2 and HBV, we found that the patients with pre-existing HBV infection will be much  
262 more vulnerable to SARS-CoV-2 infection. During the pandemic of SARS-CoV-2  
263 infection, HBV patients should be given the specific protection.

264

## 265 **Acknowledgement**

266 This study was funded by the Zhongnan Hospital of Wuhan University Science,  
267 Technology and Innovation Seed Fund, grant number znp2018007. The funders had  
268 no role in study design, data collection or analysis, decision to publish or preparation  
269 of the manuscript. The authors declared no competing interests.

270

271

## 272 **Reference**

- 273 1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, et al. Early  
274 Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.  
275 *N Engl J Med* 2020.
- 276 2. Naming the coronavirus disease (COVID-2019) and the virus that causes it.  
277 *In*; 2020.
- 278 3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis  
279 B virus infection: new estimates of age-specific HBsAg seroprevalence and  
280 endemicity. *Vaccine* 2012;30:2212-2219.
- 281 4. Polaris Observatory C. Global prevalence, treatment, and prevention of  
282 hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol*  
283 2018;3:383-403.
- 284 5. *In*: Guidelines for the Prevention, Care and Treatment of Persons with  
285 Chronic Hepatitis B Infection. Geneva, 2015.
- 286 6. Chinese Society of Hepatology CMA, Chinese Society of Infectious Diseases  
287 CMA, Hou JL, lai W. [The guideline of prevention and treatment for chronic hepatitis  
288 B: a 2015 update]. *Zhonghua Gan Zang Bing Za Zhi* 2015;23:888-905.
- 289 7. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis  
290 on the receptor ACE2 expression reveals the potential risk of different human organs  
291 vulnerable to 2019-nCoV infection. *Front Med* 2020.
- 292 8. Zhenyu Fan LC, Jun Li, Cheng Tian, Yajun Zhang, Shaoping Huang, Zhanju  
293 Liu, Jilin Cheng. Clinical Features of COVID-19 Related Liver Damage  
294 . medRxiv 2020.02.26.20026971; 2020.
- 295 9. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, et al. Clinical  
296 Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected  
297 Pneumonia in Wuhan, China. *JAMA* 2020.

- 298 10. Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, Choi KW, et al.  
299 SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases.  
300 Hepatology 2004;39:302-310.
- 301 11. Alsaad KO, Hajeer AH, Al Balwi M, Al Moaiqel M, Al Oudah N, Al Ajlan A,  
302 AlJohani S, et al. Histopathology of Middle East respiratory syndrome coronavirus  
303 (MERS-CoV) infection - clinicopathological and ultrastructural study. Histopathology  
304 2018;72:516-524.
- 305 12. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, et al. Epidemiological  
306 and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in  
307 Wuhan, China: a descriptive study. Lancet 2020;395:507-513.
- 308 13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, et al. Clinical  
309 Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
- 310 14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, et al. Clinical features  
311 of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet  
312 2020;395:497-506.
- 313 15. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, et al. Radiological  
314 findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive  
315 study. Lancet Infect Dis 2020.
- 316 16. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, et al. Clinical findings  
317 in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside  
318 of Wuhan, China: retrospective case series. BMJ 2020;368:m606.
- 319 17. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, et al. Clinical course and  
320 outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a  
321 single-centered, retrospective, observational study. Lancet Respir Med 2020.
- 322 18. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and  
323 challenges. Lancet Gastroenterol Hepatol 2020.

324

325

326

327

328

329

330

331

332

333

334

335

336

337 **Table 1.** Demographics, baseline characteristics, treatment and clinical outcomes of  
 338 123 COVID-19 patients with or without HBV infection

	Total (n=123)	With infection (n=15)	Without infection (n=108)	P value
<b>Sex</b>				<b>0.0469</b>
female	73(59.3%)	5(33.3%)	68(63.0%)	
male	50(40.7%)	10(66.7%)	40(37.0%)	
<b>Age, median (IQR), y</b>	51.0(35.0,66.0)	54.0(39.0,60.0)	51.0(35.0,66.0)	0.6127
<b>Comorbidities</b>	35(28.5%)	4(26.7%)	31(28.7%)	1.0000
Hypertension	19(15.4%)	1(6.7%)	18(16.7%)	0.4628
Cardiovascular disease	8(6.5%)	0(0.0%)	8(7.4%)	0.5939
Diabetes	12(9.8%)	1(6.7%)	11(10.2%)	1.0000
Malignancy	5(4.1%)	3(20.0%)	2(1.9%)	0.0724
COPD	5(4.1%)	0(0.0%)	5(4.6%)	1.0000
Liver cirrhosis	3(2.4%)	2(13.3%)	1(0.9%)	<b>0.0390</b>
<b>Signs and symptoms</b>				
Fever	85 (69.1%)	8 (53.3%)	77 (71.3%)	0.2310
Fatigue	67 (54.5%)	8 (53.3%)	59 (54.6%)	1.0000
Myalgia	40 (32.5%)	3 (20.0%)	37 (34.3%)	0.7604
Cough	62(50.4%)	4 (26.7%)	58 (53.7%)	0.0582
Dyspnea	26 (21.1%)	6 (40.0%)	20 (18.5%)	0.0859
Diarrhea	20 (16.3%)	2 (13.3%)	18 (16.7%)	1.0000
Headache	21 (17.1%)	2 (13.3%)	19 (17.6%)	1.0000
<b>Days from illness onset to hospital, median (IQR), d</b>	7.0(4.0,10.0)	7.0(4.0,10.0)	7.0(4.0,10.0)	0.9102

<b>Severe type</b>	33(26.8%)	7(46.7%)	26(24.1%)	0.1152
<b>Treatment</b>				
Oxygen support	74(60.2%)	8(53.3%)	66(61.1%)	0.5842
Antiviral therapy	74(60.2%)	7(12.7%)	67(62.0%)	0.2733
Antibiotic therapy	123 (100.0%)	15(100.0%)	108(100.0%)	-
Use of corticosteroid	61(49.6%)	5(33.3%)	56(51.9%)	0.2704
<b>Hospital stays, median (IQR), d</b>	14.0(9.0, 20.0)	14.0(11.0, 18.0)	14.0(9.0, 21.0)	0.9383
<b>Clinical outcome</b>				
Remained in hospital	8(6.5%)	2(13.3%)	6(5.6%)	0.0690
Discharged	110(89.4%)	11(73.4%)	99(91.6%)	
Death	5(4.1%)	2(13.3%)	3(2.8%)	

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356 **Table 2.** Laboratory results of 123 COVID-19 patients with or without HBV infection

	Normal Range	Total	With infection (n=15)	HBV Without infection (n=108)	P value
White blood cell Count ( $\times 10^9$ /L)	3.5-9.5	4.2 (3.0, 5.7)	4.4(3.4, 5.6)	4.2(2.9, 5.7)	0.6484
Lymphocyte count ( $\times 10^9$ /L)	1.1-3.2	<b>0.9 (0.6, 1.3)</b>	<b>0.7(0.4, 1.1)</b>	<b>0.9(0.6, 1.3)</b>	0.0598
Neutrophil count ( $\times 10^9$ /L)	1.8-6.3	2.5 (1.6, 3.8)	3.4(2.3, 5.3)	2.5(1.6, 3.7)	0.2091
Platelet count ( $\times 10^9$ /L)	125-350	179.0(129.0, 225.0)	186.0(104.0, 225.0)	178.5(130.3, 225.5)	0.7020
Alanine aminotransferase (U/L)	9-50	22.0 (15.0, 34.5)	25.0 (16.0, 44.0)	21.5 (15.0, 32.8)	0.4418
Aspartate aminotransferase (U/L)	15-40	25.0 (19.0, 38.0)	28.0 (19.0, 58.0)	25.0 (19.0, 37.0)	0.6327
Total bilirubin (mmol/L)	5-21	9.6 (7.8, 12.8)	13.2 (10.0, 17.4)	9.4 (7.6, 12.3)	<b>0.0178</b>
Gamma-glutamyltransferase (U/L)	8-57	22.0 (15.0, 36.0)	20.0(14.0, 28.0)	22.0(15.3, 36.8)	0.5110
Alkaline phosphatase (U/L)	30-120	66.0 (54.0, 83.0)	76.0 (52.0, 102.0)	65.0 (54.0, 79.8)	0.2339
Albumin (g/L)	40-55	38.2 (34.4, 41.0)	36.0 (30.9, 39.6)	38.3 (34.6, 41.1)	0.2309
Prothrombin time (s)	9.4-12.5	12.7 (11.7, 13.3)	13.0 (11.5, 13.9)	12.7 (11.8, 13.3)	0.2376
Activated partial thromboplastin time (s)	25.1-36.5	30.7 (28.5, 32.6)	30.6 (27.9, 32.7)	30.9 (28.6, 32.6)	0.4557
International normalized ratio	0.85-1.15	1.2 (1.1, 1.2)	1.2 (1.1, 1.3)	1.2 (1.1, 1.2)	0.2324
D-dimer, (mg/L)	0-500	204.0 (126.0, 464.0)	270.0 (101.0, 2139.0)	195.5 (128.0, 438.8)	0.4794
Creatinine ( $\mu$ mol/L).	64-104	62.9 (52.6, 76.9)	65.4 (59.0, 81.1)	61.9 (52.4, 73.5)	0.2177

357

358

359

360

361

362

363

364

365

366

367 **Table S1.** Hepatitis B serological markers of fifteen COVID-19 patients with HBV  
 368 infection

Patient	Demographics		Hepatitis B virus serological markers					
	Age (Year)	Sex (Female/Male)	HBsAg (IU/L,0-0.05)	Anti-HBsAg (IU/L,0-10)	HBeAg (s/co,0-1)	Anti-HBeAg (s/co,>1)	Anti-HbcAg (s/co,0-1)	HBV-DNA (IU/L,<20)
1	38	Male	> 250.0	NA*	NA	NA	NA	100.0
2	54	Male	425.1	NA	NA	NA	NA	NA
3	74	Male	1.8	0.00	0.40	0.03	11.31	< 20
4	36	Female	1294.0	0.07	0.95	1.11	10.72	211.0
5	48	Male	> 250.0	0.10	0.47	0.01	12.02	235.0
6	60	Male	1.1	0.74	0.44	0.03	9.67	<20
7	72	Female	558.7	0.29	0.40	0.01	11.58	40500.0
8	56	Female	148.9	0.23	0.37	0.01	10.74	40.6
9	57	Male	122.7	NA	NA	NA	NA	NA
10	39	Male	> 250.0	NA	NA	NA	NA	657.0
11	50	Female	2971.0	0.00	0.38	0.02	10.39	2180.0
12	49	Male	143.9	0.77	0.40	0.02	10.85	89.0
13	59	Male	0.2	0.38	0.01	0.01	10.39	<20
14	77	Male	5.6	5.14	0.42	0.07	10.90	166.0
15	28	Female	> 250.0	0.00	2.60	1.32	6.44	1340.0

369 \*NA, not available.

370

371